SVB Securities analyst Roanna Ruiz reiterated a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) on May 9 and set a price target of $5.00. The company’s shares opened today at $2.94.
According to TipRanks, Ruiz is an analyst with an average return of -9.3% and a 39.47% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as ARS Pharmaceuticals, Lantheus, and Pardes Biosciences.
Xeris Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $5.33, implying an 81.29% upside from current levels. In a report released yesterday, Piper Sandler also reiterated a Buy rating on the stock with a $5.00 price target.
See the top stocks recommended by analysts >>
XERS market cap is currently $402.3M and has a P/E ratio of -5.13.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
Read More on XERS:
